MedPath

The Governing Council of the University of Toronto

The Governing Council of the University of Toronto logo
🇨🇦Canada
Ownership
Private
Established
1827-03-15
Employees
10K
Market Cap
-
Website
http://www.utoronto.ca

Clinical Trials

450

Active:20
Completed:225

Trial Phases

6 Phases

Early Phase 1:4
Phase 1:20
Phase 2:26
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (363 trials with phase data)• Click on a phase to view related trials

Not Applicable
282 (77.7%)
Phase 2
26 (7.2%)
Phase 1
20 (5.5%)
Phase 3
19 (5.2%)
Phase 4
11 (3.0%)
Early Phase 1
4 (1.1%)
phase_2_3
1 (0.3%)

Feasibility of High-Intensity Interval Training, Moderate-Intensity Continuous Training, and Stretching in Perimenopausal Females

Not Applicable
Not yet recruiting
Conditions
Women
First Posted Date
2025-08-20
Last Posted Date
2025-08-20
Lead Sponsor
University of Toronto
Target Recruit Count
30
Registration Number
NCT07132385
Locations
🇨🇦

Goldring Centre for High Performance Sport, Toronto, Ontario, Canada

Community Gardens and Environmental Health in Mississauga

Not Applicable
Active, not recruiting
Conditions
Type 2 Diabetes
First Posted Date
2025-08-08
Last Posted Date
2025-08-08
Lead Sponsor
University of Toronto
Target Recruit Count
30
Registration Number
NCT07112326
Locations
🇨🇦

Parkway Green Generation Garden, Mississauga, Ontario (ON), Canada

🇨🇦

Malton Community Garden, Mississauga, Ontario, Canada

🇨🇦

Iceland Teaching Garden, Mississauga, Ontario, Canada

and more 1 locations

Community-integrated Nutrition Education to Prevent Type 2 Diabetes in Peel

Not Applicable
Not yet recruiting
Conditions
Type 2 Diabetes
First Posted Date
2025-07-10
Last Posted Date
2025-08-05
Lead Sponsor
University of Toronto
Target Recruit Count
150
Registration Number
NCT07058558
Locations
🇨🇦

University of Toronto Mississauga, Mississauga, Ontario (ON), Canada

🇨🇦

Community garden spaces across peel, Toronto, Ontario, Canada

Post-Operative Urinary Retention on Revision Knee Arthroplasty: the Role of Intrathecal Morphine

Not Applicable
Recruiting
Conditions
Arthroplasties, Knee Replacement
Anesthesia, Spinal
Nerve Block
Urinary Retention Postoperative
Interventions
First Posted Date
2025-07-03
Last Posted Date
2025-07-03
Lead Sponsor
University of Toronto
Target Recruit Count
50
Registration Number
NCT07050277
Locations
🇨🇦

Mount Sinai Hospital, Toronto, Ontario, Canada

Behavioral Interventions for Controlling Oral Behaviors

Not Applicable
Recruiting
Conditions
Temporomandibular Disorders (TMD)
Bruxism
Masseter
First Posted Date
2025-06-15
Last Posted Date
2025-06-15
Lead Sponsor
University of Toronto
Target Recruit Count
32
Registration Number
NCT07022795
Locations
🇨🇦

Faculty of Dentistry, Toronto, Ontario, Canada

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 78
  • Next

News

Precision BioSciences Reports First Clinical Evidence of Hepatitis B Gene Editing Therapy PBGENE-HBV

Precision BioSciences' PBGENE-HBV demonstrated substantial antiviral activity in all three patients in the lowest dose cohort, achieving 47-69% reductions in hepatitis B surface antigen levels.

IDEAYA Biosciences to Present Phase 2 Darovasertib Data for Uveal Melanoma at ESMO 2025

IDEAYA Biosciences will present Phase 2 clinical data on neoadjuvant darovasertib in primary uveal melanoma at the 2025 ESMO meeting in Berlin.

Global Study Links COVID-19 Infection and Adenoviral Vaccines to Guillain-Barré Syndrome Risk, Clears mRNA Vaccines

A multinational study analyzing data from over 230 million people across 20 global sites found that SARS-CoV-2 infection increases Guillain-Barré syndrome risk by approximately three times within six weeks of infection.

Neuropeutics Inc Wins AbbVie Biotech Innovators Award for Novel Neurodegenerative Disease Therapies

Neuropeutics Inc has been named the first recipient of the AbbVie Biotech Innovators Award for developing small molecules that prevent and reverse protein aggregation in neurodegenerative diseases.

Intrepid Labs Emerges from Stealth with AI-Powered Platform to Revolutionize Drug Formulation

Intrepid Labs has launched its Valiant platform, an AI-driven robotic system that reduces drug formulation development time from months to days, potentially improving clinical success rates.

Brain Cancer Canada Awards $170K for Two Glioblastoma Research Projects Targeting Treatment Resistance

Brain Cancer Canada has awarded $85,000 grants to two separate University of Toronto research teams investigating novel therapeutic approaches for glioblastoma, the most lethal brain cancer with less than 5% five-year survival rates.

Novel AI Model PROGRxN-BCa Significantly Improves NMIBC Progression Risk Prediction

A new artificial intelligence model, PROGRxN-BCa, trained on over 12,000 patients, outperforms current guideline-endorsed risk calculators for non-muscle invasive bladder cancer progression by approximately 10%.

Zenflow's Spring System Shows Durable Three-Year Benefits for BPH Patients in Landmark Study

• Zenflow's Spring System demonstrated 46% improvement in IPSS scores at 36 months post-placement, with 74% of patients achieving clinically significant symptom relief for benign prostatic hyperplasia. • The minimally invasive device maintained consistent efficacy over three years without compromising sexual function, positioning it as a leader in the emerging First-Line Interventional Therapy (FIT) category. • Results presented at the 2025 AUA Meeting represent the longest-term data among FIT interventions, with the company now advancing toward FDA approval through its multi-center BREEZE study.

Lifitegrast Shows Long-Term Safety and Efficacy for Dry Eye Disease in 7-Year Analysis

A 7-year postmarketing analysis of lifitegrast ophthalmic solution 5% (Xiidra) confirms its favorable safety profile with no new safety signals identified across nearly 800,000 patient treatment years.

GLP-1 Drugs Linked to Elevated Risk of Serious Eye Conditions in Multiple Studies

A new observational study found that people with diabetes taking GLP-1 drugs had more than twice the risk of developing neovascular age-related macular degeneration compared to those not taking the medications, with risk increasing from 0.1% to 0.2% after one year.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.